Future studies of investigating PUM2 during synaptic formation and procession in pathological conditions, such as epilepsy and schizophrenia, with a particular focus on glutamatergic signaling and resultant plasticity, could reveal mechanistic insights into these diseases and potentially lead to novel treatments. This evidence concerns the gene PUM2 and schizophrenia.